Search research articles
Contact Us
Filters
Showing results (461-470 of 497) with videos related to
Page
of 50
Sort By:
Leukemia
|
February 23, 2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
A Larocca, S Bringhen, M T Petrucci, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Hematological Oncology
|
April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
Francesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Cancer
|
August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
British Journal of Haematology
|
July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients
Francesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
The Lancet. Haematology
|
February 7, 2017
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Esther N Oliva, Caterina Alati, Valeria Santini, et al.
Annals of Hematology
|
December 6, 2018
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
Massimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, et al.
Cancer
|
February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis
Francesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Cancer
|
April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis
Francesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
Leukemia
|
November 21, 2008
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A Dispenzieri, R Kyle, G Merlini, et al.
Page
of 50
Search research articles
Search
Showing results (461-470 of 497) with videos related to
Sort By:
Page
of 50
Leukemia
|
February 23, 2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
A Larocca, S Bringhen, M T Petrucci, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Hematological Oncology
|
April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
Francesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Cancer
|
August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
British Journal of Haematology
|
July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients
Francesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
The Lancet. Haematology
|
February 7, 2017
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Esther N Oliva, Caterina Alati, Valeria Santini, et al.
Annals of Hematology
|
December 6, 2018
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
Massimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, et al.
Cancer
|
February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis
Francesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Cancer
|
April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis
Francesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
Leukemia
|
November 21, 2008
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A Dispenzieri, R Kyle, G Merlini, et al.
Page
of 50